▶ 調査レポート

世界の腎細胞がん臨床試験パイプライン市場規模・現状・予測(2021年-2027年)

• 英文タイトル:Global Renal Cell Carcinoma Clinical Trial Pipeline Market Size, Status and Forecast 2021-2027

QYResearchが調査・発行した産業分析レポートです。世界の腎細胞がん臨床試験パイプライン市場規模・現状・予測(2021年-2027年) / Global Renal Cell Carcinoma Clinical Trial Pipeline Market Size, Status and Forecast 2021-2027 / QFJ1-4808資料のイメージです。• レポートコード:QFJ1-4808
• 出版社/出版日:QYResearch / 2021年6月
※2024年版があります。お問い合わせください。

• レポート形態:英文、PDF、106ページ
• 納品方法:Eメール(納期:3日)
• 産業分類:医療
• 販売価格(消費税別)
  Single User¥577,200 (USD3,900)▷ お問い合わせ
  Multi User¥865,800 (USD5,850)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
QYResearch社発行の本調査レポートでは、腎細胞がん臨床試験パイプラインの世界市場(2016年~2027年)を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模(標的療法、免疫療法)、用途別市場規模(病院、研究所、商業、その他)、主要地域別市場規模(北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等)、企業情報などをまとめております。
・市場概要
・腎細胞がん臨床試験パイプラインの市場動向
・企業の競争状況、市場シェア
・腎細胞がん臨床試験パイプラインの種類別市場規模と予測2016-2027(標的療法、免疫療法)
・腎細胞がん臨床試験パイプラインの用途別市場規模と予測2016-2027(病院、研究所、商業、その他)
・腎細胞がん臨床試験パイプラインの北米市場規模2016-2027(アメリカ、カナダ)
・腎細胞がん臨床試験パイプラインの欧州市場規模2016-2027(ドイツ、フランス、イギリス等)
・腎細胞がん臨床試験パイプラインのアジア市場規模2016-2027(日本、中国、韓国、インド、東南アジア等)
・腎細胞がん臨床試験パイプラインの中南米市場規模2016-2027(メキシコ、ブラジル)
・腎細胞がん臨床試験パイプラインの中東・アフリカ市場規模2016-2027(トルコ、サウジアラビア等)
・主要企業情報(Amgen、Argos Therapeutics、AstraZeneca、Aveo Pharmaceuticals、Bayer、Exelixis、Incyte、Merck KGaA、Roche、Novartis、Pfizer、Prometheus Labs)
・結論

Market Analysis and Insights: Global Renal Cell Carcinoma Clinical Trial Pipeline Market
The global Renal Cell Carcinoma Clinical Trial Pipeline market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Renal Cell Carcinoma Clinical Trial Pipeline market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Renal Cell Carcinoma Clinical Trial Pipeline market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Renal Cell Carcinoma Clinical Trial Pipeline market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Renal Cell Carcinoma Clinical Trial Pipeline market.

Global Renal Cell Carcinoma Clinical Trial Pipeline Scope and Market Size
Renal Cell Carcinoma Clinical Trial Pipeline market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Renal Cell Carcinoma Clinical Trial Pipeline market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Targeted Therapy
Immunotherapy

Segment by Application
Hospital
Research Institute
Commercial
Other

By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Amgen
Argos Therapeutics
AstraZeneca
Aveo Pharmaceuticals
Bayer
Exelixis
Incyte
Merck KGaA
Roche
Novartis
Pfizer
Prometheus Labs

レポート目次

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Renal Cell Carcinoma Clinical Trial Pipeline Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Targeted Therapy
1.2.3 Immunotherapy
1.3 Market by Application
1.3.1 Global Renal Cell Carcinoma Clinical Trial Pipeline Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospital
1.3.3 Research Institute
1.3.4 Commercial
1.3.5 Other
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Renal Cell Carcinoma Clinical Trial Pipeline Market Perspective (2016-2027)
2.2 Renal Cell Carcinoma Clinical Trial Pipeline Growth Trends by Regions
2.2.1 Renal Cell Carcinoma Clinical Trial Pipeline Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Renal Cell Carcinoma Clinical Trial Pipeline Historic Market Share by Regions (2016-2021)
2.2.3 Renal Cell Carcinoma Clinical Trial Pipeline Forecasted Market Size by Regions (2022-2027)
2.3 Renal Cell Carcinoma Clinical Trial Pipeline Industry Dynamic
2.3.1 Renal Cell Carcinoma Clinical Trial Pipeline Market Trends
2.3.2 Renal Cell Carcinoma Clinical Trial Pipeline Market Drivers
2.3.3 Renal Cell Carcinoma Clinical Trial Pipeline Market Challenges
2.3.4 Renal Cell Carcinoma Clinical Trial Pipeline Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Renal Cell Carcinoma Clinical Trial Pipeline Players by Revenue
3.1.1 Global Top Renal Cell Carcinoma Clinical Trial Pipeline Players by Revenue (2016-2021)
3.1.2 Global Renal Cell Carcinoma Clinical Trial Pipeline Revenue Market Share by Players (2016-2021)
3.2 Global Renal Cell Carcinoma Clinical Trial Pipeline Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Renal Cell Carcinoma Clinical Trial Pipeline Revenue
3.4 Global Renal Cell Carcinoma Clinical Trial Pipeline Market Concentration Ratio
3.4.1 Global Renal Cell Carcinoma Clinical Trial Pipeline Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Renal Cell Carcinoma Clinical Trial Pipeline Revenue in 2020
3.5 Renal Cell Carcinoma Clinical Trial Pipeline Key Players Head office and Area Served
3.6 Key Players Renal Cell Carcinoma Clinical Trial Pipeline Product Solution and Service
3.7 Date of Enter into Renal Cell Carcinoma Clinical Trial Pipeline Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Renal Cell Carcinoma Clinical Trial Pipeline Breakdown Data by Type
4.1 Global Renal Cell Carcinoma Clinical Trial Pipeline Historic Market Size by Type (2016-2021)
4.2 Global Renal Cell Carcinoma Clinical Trial Pipeline Forecasted Market Size by Type (2022-2027)

5 Renal Cell Carcinoma Clinical Trial Pipeline Breakdown Data by Application
5.1 Global Renal Cell Carcinoma Clinical Trial Pipeline Historic Market Size by Application (2016-2021)
5.2 Global Renal Cell Carcinoma Clinical Trial Pipeline Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Renal Cell Carcinoma Clinical Trial Pipeline Market Size (2016-2027)
6.2 North America Renal Cell Carcinoma Clinical Trial Pipeline Market Size by Type
6.2.1 North America Renal Cell Carcinoma Clinical Trial Pipeline Market Size by Type (2016-2021)
6.2.2 North America Renal Cell Carcinoma Clinical Trial Pipeline Market Size by Type (2022-2027)
6.2.3 North America Renal Cell Carcinoma Clinical Trial Pipeline Market Size by Type (2016-2027)
6.3 North America Renal Cell Carcinoma Clinical Trial Pipeline Market Size by Application
6.3.1 North America Renal Cell Carcinoma Clinical Trial Pipeline Market Size by Application (2016-2021)
6.3.2 North America Renal Cell Carcinoma Clinical Trial Pipeline Market Size by Application (2022-2027)
6.3.3 North America Renal Cell Carcinoma Clinical Trial Pipeline Market Size by Application (2016-2027)
6.4 North America Renal Cell Carcinoma Clinical Trial Pipeline Market Size by Country
6.4.1 North America Renal Cell Carcinoma Clinical Trial Pipeline Market Size by Country (2016-2021)
6.4.2 North America Renal Cell Carcinoma Clinical Trial Pipeline Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada

7 Europe
7.1 Europe Renal Cell Carcinoma Clinical Trial Pipeline Market Size (2016-2027)
7.2 Europe Renal Cell Carcinoma Clinical Trial Pipeline Market Size by Type
7.2.1 Europe Renal Cell Carcinoma Clinical Trial Pipeline Market Size by Type (2016-2021)
7.2.2 Europe Renal Cell Carcinoma Clinical Trial Pipeline Market Size by Type (2022-2027)
7.2.3 Europe Renal Cell Carcinoma Clinical Trial Pipeline Market Size by Type (2016-2027)
7.3 Europe Renal Cell Carcinoma Clinical Trial Pipeline Market Size by Application
7.3.1 Europe Renal Cell Carcinoma Clinical Trial Pipeline Market Size by Application (2016-2021)
7.3.2 Europe Renal Cell Carcinoma Clinical Trial Pipeline Market Size by Application (2022-2027)
7.3.3 Europe Renal Cell Carcinoma Clinical Trial Pipeline Market Size by Application (2016-2027)
7.4 Europe Renal Cell Carcinoma Clinical Trial Pipeline Market Size by Country
7.4.1 Europe Renal Cell Carcinoma Clinical Trial Pipeline Market Size by Country (2016-2021)
7.4.2 Europe Renal Cell Carcinoma Clinical Trial Pipeline Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Renal Cell Carcinoma Clinical Trial Pipeline Market Size (2016-2027)
8.2 Asia-Pacific Renal Cell Carcinoma Clinical Trial Pipeline Market Size by Type
8.2.1 Asia-Pacific Renal Cell Carcinoma Clinical Trial Pipeline Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Renal Cell Carcinoma Clinical Trial Pipeline Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Renal Cell Carcinoma Clinical Trial Pipeline Market Size by Type (2016-2027)
8.3 Asia-Pacific Renal Cell Carcinoma Clinical Trial Pipeline Market Size by Application
8.3.1 Asia-Pacific Renal Cell Carcinoma Clinical Trial Pipeline Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Renal Cell Carcinoma Clinical Trial Pipeline Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Renal Cell Carcinoma Clinical Trial Pipeline Market Size by Application (2016-2027)
8.4 Asia-Pacific Renal Cell Carcinoma Clinical Trial Pipeline Market Size by Region
8.4.1 Asia-Pacific Renal Cell Carcinoma Clinical Trial Pipeline Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Renal Cell Carcinoma Clinical Trial Pipeline Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Renal Cell Carcinoma Clinical Trial Pipeline Market Size (2016-2027)
9.2 Latin America Renal Cell Carcinoma Clinical Trial Pipeline Market Size by Type
9.2.1 Latin America Renal Cell Carcinoma Clinical Trial Pipeline Market Size by Type (2016-2021)
9.2.2 Latin America Renal Cell Carcinoma Clinical Trial Pipeline Market Size by Type (2022-2027)
9.2.3 Latin America Renal Cell Carcinoma Clinical Trial Pipeline Market Size by Type (2016-2027)
9.3 Latin America Renal Cell Carcinoma Clinical Trial Pipeline Market Size by Application
9.3.1 Latin America Renal Cell Carcinoma Clinical Trial Pipeline Market Size by Application (2016-2021)
9.3.2 Latin America Renal Cell Carcinoma Clinical Trial Pipeline Market Size by Application (2022-2027)
9.3.3 Latin America Renal Cell Carcinoma Clinical Trial Pipeline Market Size by Application (2016-2027)
9.4 Latin America Renal Cell Carcinoma Clinical Trial Pipeline Market Size by Country
9.4.1 Latin America Renal Cell Carcinoma Clinical Trial Pipeline Market Size by Country (2016-2021)
9.4.2 Latin America Renal Cell Carcinoma Clinical Trial Pipeline Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Renal Cell Carcinoma Clinical Trial Pipeline Market Size (2016-2027)
10.2 Middle East & Africa Renal Cell Carcinoma Clinical Trial Pipeline Market Size by Type
10.2.1 Middle East & Africa Renal Cell Carcinoma Clinical Trial Pipeline Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Renal Cell Carcinoma Clinical Trial Pipeline Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Renal Cell Carcinoma Clinical Trial Pipeline Market Size by Type (2016-2027)
10.3 Middle East & Africa Renal Cell Carcinoma Clinical Trial Pipeline Market Size by Application
10.3.1 Middle East & Africa Renal Cell Carcinoma Clinical Trial Pipeline Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Renal Cell Carcinoma Clinical Trial Pipeline Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Renal Cell Carcinoma Clinical Trial Pipeline Market Size by Application (2016-2027)
10.4 Middle East & Africa Renal Cell Carcinoma Clinical Trial Pipeline Market Size by Country
10.4.1 Middle East & Africa Renal Cell Carcinoma Clinical Trial Pipeline Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Renal Cell Carcinoma Clinical Trial Pipeline Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Amgen
11.1.1 Amgen Company Details
11.1.2 Amgen Business Overview
11.1.3 Amgen Renal Cell Carcinoma Clinical Trial Pipeline Introduction
11.1.4 Amgen Revenue in Renal Cell Carcinoma Clinical Trial Pipeline Business (2016-2021)
11.1.5 Amgen Recent Development
11.2 Argos Therapeutics
11.2.1 Argos Therapeutics Company Details
11.2.2 Argos Therapeutics Business Overview
11.2.3 Argos Therapeutics Renal Cell Carcinoma Clinical Trial Pipeline Introduction
11.2.4 Argos Therapeutics Revenue in Renal Cell Carcinoma Clinical Trial Pipeline Business (2016-2021)
11.2.5 Argos Therapeutics Recent Development
11.3 AstraZeneca
11.3.1 AstraZeneca Company Details
11.3.2 AstraZeneca Business Overview
11.3.3 AstraZeneca Renal Cell Carcinoma Clinical Trial Pipeline Introduction
11.3.4 AstraZeneca Revenue in Renal Cell Carcinoma Clinical Trial Pipeline Business (2016-2021)
11.3.5 AstraZeneca Recent Development
11.4 Aveo Pharmaceuticals
11.4.1 Aveo Pharmaceuticals Company Details
11.4.2 Aveo Pharmaceuticals Business Overview
11.4.3 Aveo Pharmaceuticals Renal Cell Carcinoma Clinical Trial Pipeline Introduction
11.4.4 Aveo Pharmaceuticals Revenue in Renal Cell Carcinoma Clinical Trial Pipeline Business (2016-2021)
11.4.5 Aveo Pharmaceuticals Recent Development
11.5 Bayer
11.5.1 Bayer Company Details
11.5.2 Bayer Business Overview
11.5.3 Bayer Renal Cell Carcinoma Clinical Trial Pipeline Introduction
11.5.4 Bayer Revenue in Renal Cell Carcinoma Clinical Trial Pipeline Business (2016-2021)
11.5.5 Bayer Recent Development
11.6 Exelixis
11.6.1 Exelixis Company Details
11.6.2 Exelixis Business Overview
11.6.3 Exelixis Renal Cell Carcinoma Clinical Trial Pipeline Introduction
11.6.4 Exelixis Revenue in Renal Cell Carcinoma Clinical Trial Pipeline Business (2016-2021)
11.6.5 Exelixis Recent Development
11.7 Incyte
11.7.1 Incyte Company Details
11.7.2 Incyte Business Overview
11.7.3 Incyte Renal Cell Carcinoma Clinical Trial Pipeline Introduction
11.7.4 Incyte Revenue in Renal Cell Carcinoma Clinical Trial Pipeline Business (2016-2021)
11.7.5 Incyte Recent Development
11.8 Merck KGaA
11.8.1 Merck KGaA Company Details
11.8.2 Merck KGaA Business Overview
11.8.3 Merck KGaA Renal Cell Carcinoma Clinical Trial Pipeline Introduction
11.8.4 Merck KGaA Revenue in Renal Cell Carcinoma Clinical Trial Pipeline Business (2016-2021)
11.8.5 Merck KGaA Recent Development
11.9 Roche
11.9.1 Roche Company Details
11.9.2 Roche Business Overview
11.9.3 Roche Renal Cell Carcinoma Clinical Trial Pipeline Introduction
11.9.4 Roche Revenue in Renal Cell Carcinoma Clinical Trial Pipeline Business (2016-2021)
11.9.5 Roche Recent Development
11.10 Novartis
11.10.1 Novartis Company Details
11.10.2 Novartis Business Overview
11.10.3 Novartis Renal Cell Carcinoma Clinical Trial Pipeline Introduction
11.10.4 Novartis Revenue in Renal Cell Carcinoma Clinical Trial Pipeline Business (2016-2021)
11.10.5 Novartis Recent Development
11.11 Pfizer
11.11.1 Pfizer Company Details
11.11.2 Pfizer Business Overview
11.11.3 Pfizer Renal Cell Carcinoma Clinical Trial Pipeline Introduction
11.11.4 Pfizer Revenue in Renal Cell Carcinoma Clinical Trial Pipeline Business (2016-2021)
11.11.5 Pfizer Recent Development
11.12 Prometheus Labs
11.12.1 Prometheus Labs Company Details
11.12.2 Prometheus Labs Business Overview
11.12.3 Prometheus Labs Renal Cell Carcinoma Clinical Trial Pipeline Introduction
11.12.4 Prometheus Labs Revenue in Renal Cell Carcinoma Clinical Trial Pipeline Business (2016-2021)
11.12.5 Prometheus Labs Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Renal Cell Carcinoma Clinical Trial Pipeline Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Targeted Therapy
Table 3. Key Players of Immunotherapy
Table 4. Global Renal Cell Carcinoma Clinical Trial Pipeline Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 5. Global Renal Cell Carcinoma Clinical Trial Pipeline Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 6. Global Renal Cell Carcinoma Clinical Trial Pipeline Market Size by Regions (2016-2021) & (US$ Million)
Table 7. Global Renal Cell Carcinoma Clinical Trial Pipeline Market Share by Regions (2016-2021)
Table 8. Global Renal Cell Carcinoma Clinical Trial Pipeline Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 9. Global Renal Cell Carcinoma Clinical Trial Pipeline Market Share by Regions (2022-2027)
Table 10. Renal Cell Carcinoma Clinical Trial Pipeline Market Trends
Table 11. Renal Cell Carcinoma Clinical Trial Pipeline Market Drivers
Table 12. Renal Cell Carcinoma Clinical Trial Pipeline Market Challenges
Table 13. Renal Cell Carcinoma Clinical Trial Pipeline Market Restraints
Table 14. Global Renal Cell Carcinoma Clinical Trial Pipeline Revenue by Players (2016-2021) & (US$ Million)
Table 15. Global Renal Cell Carcinoma Clinical Trial Pipeline Market Share by Players (2016-2021)
Table 16. Global Top Renal Cell Carcinoma Clinical Trial Pipeline Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Renal Cell Carcinoma Clinical Trial Pipeline as of 2020)
Table 17. Ranking of Global Top Renal Cell Carcinoma Clinical Trial Pipeline Companies by Revenue (US$ Million) in 2020
Table 18. Global 5 Largest Players Market Share by Renal Cell Carcinoma Clinical Trial Pipeline Revenue (CR5 and HHI) & (2016-2021)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Renal Cell Carcinoma Clinical Trial Pipeline Product Solution and Service
Table 21. Date of Enter into Renal Cell Carcinoma Clinical Trial Pipeline Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Renal Cell Carcinoma Clinical Trial Pipeline Market Size by Type (2016-2021) (US$ Million)
Table 24. Global Renal Cell Carcinoma Clinical Trial Pipeline Revenue Market Share by Type (2016-2021)
Table 25. Global Renal Cell Carcinoma Clinical Trial Pipeline Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 26. Global Renal Cell Carcinoma Clinical Trial Pipeline Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 27. Global Renal Cell Carcinoma Clinical Trial Pipeline Market Size Share by Application (2016-2021) & (US$ Million)
Table 28. Global Renal Cell Carcinoma Clinical Trial Pipeline Revenue Market Share by Application (2016-2021)
Table 29. Global Renal Cell Carcinoma Clinical Trial Pipeline Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 30. Global Renal Cell Carcinoma Clinical Trial Pipeline Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 31. North America Renal Cell Carcinoma Clinical Trial Pipeline Market Size by Type (2016-2021) (US$ Million)
Table 32. North America Renal Cell Carcinoma Clinical Trial Pipeline Market Size by Type (2022-2027) & (US$ Million)
Table 33. North America Renal Cell Carcinoma Clinical Trial Pipeline Market Size by Application (2016-2021) (US$ Million)
Table 34. North America Renal Cell Carcinoma Clinical Trial Pipeline Market Size by Application (2022-2027) & (US$ Million)
Table 35. North America Renal Cell Carcinoma Clinical Trial Pipeline Market Size by Country (2016-2021) & (US$ Million)
Table 36. North America Renal Cell Carcinoma Clinical Trial Pipeline Market Size by Country (2022-2027) & (US$ Million)
Table 37. Europe Renal Cell Carcinoma Clinical Trial Pipeline Market Size by Type (2016-2021) (US$ Million)
Table 38. Europe Renal Cell Carcinoma Clinical Trial Pipeline Market Size by Type (2022-2027) & (US$ Million)
Table 39. Europe Renal Cell Carcinoma Clinical Trial Pipeline Market Size by Application (2016-2021) (US$ Million)
Table 40. Europe Renal Cell Carcinoma Clinical Trial Pipeline Market Size by Application (2022-2027) & (US$ Million)
Table 41. Europe Renal Cell Carcinoma Clinical Trial Pipeline Market Size by Country (2016-2021) & (US$ Million)
Table 42. Europe Renal Cell Carcinoma Clinical Trial Pipeline Market Size by Country (2022-2027) & (US$ Million)
Table 43. Asia-Pacific Renal Cell Carcinoma Clinical Trial Pipeline Market Size by Type (2016-2021) (US$ Million)
Table 44. Asia-Pacific Renal Cell Carcinoma Clinical Trial Pipeline Market Size by Type (2022-2027) & (US$ Million)
Table 45. Asia-Pacific Renal Cell Carcinoma Clinical Trial Pipeline Market Size by Application (2016-2021) (US$ Million)
Table 46. Asia-Pacific Renal Cell Carcinoma Clinical Trial Pipeline Market Size by Application (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Renal Cell Carcinoma Clinical Trial Pipeline Market Size by Region (2016-2021) & (US$ Million)
Table 48. Asia-Pacific Renal Cell Carcinoma Clinical Trial Pipeline Market Size by Region (2022-2027) & (US$ Million)
Table 49. Latin America Renal Cell Carcinoma Clinical Trial Pipeline Market Size by Type (2016-2021) (US$ Million)
Table 50. Latin America Renal Cell Carcinoma Clinical Trial Pipeline Market Size by Type (2022-2027) & (US$ Million)
Table 51. Latin America Renal Cell Carcinoma Clinical Trial Pipeline Market Size by Application (2016-2021) (US$ Million)
Table 52. Latin America Renal Cell Carcinoma Clinical Trial Pipeline Market Size by Application (2022-2027) & (US$ Million)
Table 53. Latin America Renal Cell Carcinoma Clinical Trial Pipeline Market Size by Country (2016-2021) & (US$ Million)
Table 54. Latin America Renal Cell Carcinoma Clinical Trial Pipeline Market Size by Country (2022-2027) & (US$ Million)
Table 55. Middle East & Africa Renal Cell Carcinoma Clinical Trial Pipeline Market Size by Type (2016-2021) (US$ Million)
Table 56. Middle East & Africa Renal Cell Carcinoma Clinical Trial Pipeline Market Size by Type (2022-2027) & (US$ Million)
Table 57. Middle East & Africa Renal Cell Carcinoma Clinical Trial Pipeline Market Size by Application (2016-2021) (US$ Million)
Table 58. Middle East & Africa Renal Cell Carcinoma Clinical Trial Pipeline Market Size by Application (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Renal Cell Carcinoma Clinical Trial Pipeline Market Size by Country (2016-2021) & (US$ Million)
Table 60. Middle East & Africa Renal Cell Carcinoma Clinical Trial Pipeline Market Size by Country (2022-2027) & (US$ Million)
Table 61. Amgen Company Details
Table 62. Amgen Business Overview
Table 63. Amgen Renal Cell Carcinoma Clinical Trial Pipeline Product
Table 64. Amgen Revenue in Renal Cell Carcinoma Clinical Trial Pipeline Business (2016-2021) & (US$ Million)
Table 65. Amgen Recent Development
Table 66. Argos Therapeutics Company Details
Table 67. Argos Therapeutics Business Overview
Table 68. Argos Therapeutics Renal Cell Carcinoma Clinical Trial Pipeline Product
Table 69. Argos Therapeutics Revenue in Renal Cell Carcinoma Clinical Trial Pipeline Business (2016-2021) & (US$ Million)
Table 70. Argos Therapeutics Recent Development
Table 71. AstraZeneca Company Details
Table 72. AstraZeneca Business Overview
Table 73. AstraZeneca Renal Cell Carcinoma Clinical Trial Pipeline Product
Table 74. AstraZeneca Revenue in Renal Cell Carcinoma Clinical Trial Pipeline Business (2016-2021) & (US$ Million)
Table 75. AstraZeneca Recent Development
Table 76. Aveo Pharmaceuticals Company Details
Table 77. Aveo Pharmaceuticals Business Overview
Table 78. Aveo Pharmaceuticals Renal Cell Carcinoma Clinical Trial Pipeline Product
Table 79. Aveo Pharmaceuticals Revenue in Renal Cell Carcinoma Clinical Trial Pipeline Business (2016-2021) & (US$ Million)
Table 80. Aveo Pharmaceuticals Recent Development
Table 81. Bayer Company Details
Table 82. Bayer Business Overview
Table 83. Bayer Renal Cell Carcinoma Clinical Trial Pipeline Product
Table 84. Bayer Revenue in Renal Cell Carcinoma Clinical Trial Pipeline Business (2016-2021) & (US$ Million)
Table 85. Bayer Recent Development
Table 86. Exelixis Company Details
Table 87. Exelixis Business Overview
Table 88. Exelixis Renal Cell Carcinoma Clinical Trial Pipeline Product
Table 89. Exelixis Revenue in Renal Cell Carcinoma Clinical Trial Pipeline Business (2016-2021) & (US$ Million)
Table 90. Exelixis Recent Development
Table 91. Incyte Company Details
Table 92. Incyte Business Overview
Table 93. Incyte Renal Cell Carcinoma Clinical Trial Pipeline Product
Table 94. Incyte Revenue in Renal Cell Carcinoma Clinical Trial Pipeline Business (2016-2021) & (US$ Million)
Table 95. Incyte Recent Development
Table 96. Merck KGaA Company Details
Table 97. Merck KGaA Business Overview
Table 98. Merck KGaA Revenue in Renal Cell Carcinoma Clinical Trial Pipeline Business (2016-2021) & (US$ Million)
Table 99. Merck KGaA Recent Development
Table 100. Roche Company Details
Table 101. Roche Business Overview
Table 102. Roche Renal Cell Carcinoma Clinical Trial Pipeline Product
Table 103. Roche Revenue in Renal Cell Carcinoma Clinical Trial Pipeline Business (2016-2021) & (US$ Million)
Table 104. Roche Recent Development
Table 105. Novartis Company Details
Table 106. Novartis Business Overview
Table 107. Novartis Renal Cell Carcinoma Clinical Trial Pipeline Product
Table 108. Novartis Revenue in Renal Cell Carcinoma Clinical Trial Pipeline Business (2016-2021) & (US$ Million)
Table 109. Novartis Recent Development
Table 110. Pfizer Company Details
Table 111. Pfizer Business Overview
Table 112. Pfizer Renal Cell Carcinoma Clinical Trial Pipeline Product
Table 113. Pfizer Revenue in Renal Cell Carcinoma Clinical Trial Pipeline Business (2016-2021) & (US$ Million)
Table 114. Pfizer Recent Development
Table 115. Prometheus Labs Company Details
Table 116. Prometheus Labs Business Overview
Table 117. Prometheus Labs Renal Cell Carcinoma Clinical Trial Pipeline Product
Table 118. Prometheus Labs Revenue in Renal Cell Carcinoma Clinical Trial Pipeline Business (2016-2021) & (US$ Million)
Table 119. Prometheus Labs Recent Development
Table 120. Research Programs/Design for This Report
Table 121. Key Data Information from Secondary Sources
Table 122. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Renal Cell Carcinoma Clinical Trial Pipeline Market Share by Type: 2020 VS 2027
Figure 2. Targeted Therapy Features
Figure 3. Immunotherapy Features
Figure 4. Global Renal Cell Carcinoma Clinical Trial Pipeline Market Share by Application: 2020 VS 2027
Figure 5. Hospital Case Studies
Figure 6. Research Institute Case Studies
Figure 7. Commercial Case Studies
Figure 8. Other Case Studies
Figure 9. Renal Cell Carcinoma Clinical Trial Pipeline Report Years Considered
Figure 10. Global Renal Cell Carcinoma Clinical Trial Pipeline Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 11. Global Renal Cell Carcinoma Clinical Trial Pipeline Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 12. Global Renal Cell Carcinoma Clinical Trial Pipeline Market Share by Regions: 2020 VS 2027
Figure 13. Global Renal Cell Carcinoma Clinical Trial Pipeline Market Share by Regions (2022-2027)
Figure 14. Global Renal Cell Carcinoma Clinical Trial Pipeline Market Share by Players in 2020
Figure 15. Global Top Renal Cell Carcinoma Clinical Trial Pipeline Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Renal Cell Carcinoma Clinical Trial Pipeline as of 2020
Figure 16. The Top 10 and 5 Players Market Share by Renal Cell Carcinoma Clinical Trial Pipeline Revenue in 2020
Figure 17. Global Renal Cell Carcinoma Clinical Trial Pipeline Revenue Market Share by Type (2016-2021)
Figure 18. Global Renal Cell Carcinoma Clinical Trial Pipeline Revenue Market Share by Type (2022-2027)
Figure 19. North America Renal Cell Carcinoma Clinical Trial Pipeline Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 20. North America Renal Cell Carcinoma Clinical Trial Pipeline Market Share by Type (2016-2027)
Figure 21. North America Renal Cell Carcinoma Clinical Trial Pipeline Market Share by Application (2016-2027)
Figure 22. North America Renal Cell Carcinoma Clinical Trial Pipeline Market Share by Country (2016-2027)
Figure 23. United States Renal Cell Carcinoma Clinical Trial Pipeline Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 24. Canada Renal Cell Carcinoma Clinical Trial Pipeline Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Europe Renal Cell Carcinoma Clinical Trial Pipeline Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Europe Renal Cell Carcinoma Clinical Trial Pipeline Market Share by Type (2016-2027)
Figure 27. Europe Renal Cell Carcinoma Clinical Trial Pipeline Market Share by Application (2016-2027)
Figure 28. Europe Renal Cell Carcinoma Clinical Trial Pipeline Market Share by Country (2016-2027)
Figure 29. Germany Renal Cell Carcinoma Clinical Trial Pipeline Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. France Renal Cell Carcinoma Clinical Trial Pipeline Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. U.K. Renal Cell Carcinoma Clinical Trial Pipeline Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. Italy Renal Cell Carcinoma Clinical Trial Pipeline Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Russia Renal Cell Carcinoma Clinical Trial Pipeline Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Nordic Renal Cell Carcinoma Clinical Trial Pipeline Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Asia-Pacific Renal Cell Carcinoma Clinical Trial Pipeline Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Asia-Pacific Renal Cell Carcinoma Clinical Trial Pipeline Market Share by Type (2016-2027)
Figure 37. Asia-Pacific Renal Cell Carcinoma Clinical Trial Pipeline Market Share by Application (2016-2027)
Figure 38. Asia-Pacific Renal Cell Carcinoma Clinical Trial Pipeline Market Share by Region (2016-2027)
Figure 39. China Renal Cell Carcinoma Clinical Trial Pipeline Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. Japan Renal Cell Carcinoma Clinical Trial Pipeline Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. South Korea Renal Cell Carcinoma Clinical Trial Pipeline Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. Southeast Asia Renal Cell Carcinoma Clinical Trial Pipeline Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. India Renal Cell Carcinoma Clinical Trial Pipeline Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Australia Renal Cell Carcinoma Clinical Trial Pipeline Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Latin America Renal Cell Carcinoma Clinical Trial Pipeline Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Latin America Renal Cell Carcinoma Clinical Trial Pipeline Market Share by Type (2016-2027)
Figure 47. Latin America Renal Cell Carcinoma Clinical Trial Pipeline Market Share by Application (2016-2027)
Figure 48. Latin America Renal Cell Carcinoma Clinical Trial Pipeline Market Share by Country (2016-2027)
Figure 49. Mexico Renal Cell Carcinoma Clinical Trial Pipeline Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Brazil Renal Cell Carcinoma Clinical Trial Pipeline Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Middle East & Africa Renal Cell Carcinoma Clinical Trial Pipeline Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Middle East & Africa Renal Cell Carcinoma Clinical Trial Pipeline Market Share by Type (2016-2027)
Figure 53. Middle East & Africa Renal Cell Carcinoma Clinical Trial Pipeline Market Share by Application (2016-2027)
Figure 54. Middle East & Africa Renal Cell Carcinoma Clinical Trial Pipeline Market Share by Country (2016-2027)
Figure 55. Turkey Renal Cell Carcinoma Clinical Trial Pipeline Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. Saudi Arabia Renal Cell Carcinoma Clinical Trial Pipeline Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. UAE Renal Cell Carcinoma Clinical Trial Pipeline Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. Amgen Revenue Growth Rate in Renal Cell Carcinoma Clinical Trial Pipeline Business (2016-2021)
Figure 59. Argos Therapeutics Revenue Growth Rate in Renal Cell Carcinoma Clinical Trial Pipeline Business (2016-2021)
Figure 60. AstraZeneca Revenue Growth Rate in Renal Cell Carcinoma Clinical Trial Pipeline Business (2016-2021)
Figure 61. Aveo Pharmaceuticals Revenue Growth Rate in Renal Cell Carcinoma Clinical Trial Pipeline Business (2016-2021)
Figure 62. Bayer Revenue Growth Rate in Renal Cell Carcinoma Clinical Trial Pipeline Business (2016-2021)
Figure 63. Exelixis Revenue Growth Rate in Renal Cell Carcinoma Clinical Trial Pipeline Business (2016-2021)
Figure 64. Incyte Revenue Growth Rate in Renal Cell Carcinoma Clinical Trial Pipeline Business (2016-2021)
Figure 65. Merck KGaA Revenue Growth Rate in Renal Cell Carcinoma Clinical Trial Pipeline Business (2016-2021)
Figure 66. Roche Revenue Growth Rate in Renal Cell Carcinoma Clinical Trial Pipeline Business (2016-2021)
Figure 67. Novartis Revenue Growth Rate in Renal Cell Carcinoma Clinical Trial Pipeline Business (2016-2021)
Figure 68. Pfizer Revenue Growth Rate in Renal Cell Carcinoma Clinical Trial Pipeline Business (2016-2021)
Figure 69. Prometheus Labs Revenue Growth Rate in Renal Cell Carcinoma Clinical Trial Pipeline Business (2016-2021)
Figure 70. Bottom-up and Top-down Approaches for This Report
Figure 71. Data Triangulation
Figure 72. Key Executives Interviewed